| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424685000 | Aluminum chloride or bromide | 6 |
| 20080260864 | Topical Compositions for the Treatment of Depilation-Induced Irritation or Prevention Thereof - The present invention relates to topical compositions comprising as active ingredients Aluminium Chloride and Sulfur for treatment of skin irritation induced by depilation. Said compositions have pharmaceutical and/or cosmetic and/or quasi cosmetic properties. The present invention also involves methods of making and methods of using such compositions. Furthermore, the present invention consists of a method for prevention and/or treatment of skin irritation induced by depilation. | 10-23-2008 |
| 20100215775 | USE OF C10-C14-ALKANEDIOLS IN THE PREPARATION OF A COMPOSITION FOR THE PROPHYLAXIS AND/OR TREATMENT OF MALASSEZIA-INDUCED DANDRUFF FORMATION - The invention relates to the use of C10-C14-alkane-1,2-diols, in particular 1,2-decanediol, 1,2-dodecanediol and/or 1,2-tetradecanediol, in the preparation of a composition for the prophylaxis and/or treatment of | 08-26-2010 |
| 20120164239 | COMPOSITION AND METHOD FOR TREATING WOOD-BASED MATERIAL AND WOOD-BASED MATERIAL TREATED WITH COMPOSITION - A composition for treating wood-based material including at least one C | 06-28-2012 |
| 20160015637 | ANTI-ITCHING POWDER - The present invention is anti-itching powder that blocks transmission to stratum corneum and invasion up to epidermal cells by emulsion as a result of further concentration on skin stratum corneum. The emulsion is produced by mixing sweat continuously secreted during rest and sebum. The emulsion becomes a cell disorder composition. Specifically, the anti-itching powder as a fine powder contains main ingredients of aluminum chloride or alum and cyclodextrin. A fine powder as a base is dispersed into and combined with the fine powder. The application of the fine powder over the skin prevents sudden itch without blocking emission and transpiration of moisture in the sweat from the skin stratum corneum. | 01-21-2016 |
| 20160136324 | BIOLOGICAL FILM-FORMING AGENT FOR FACILITATION OF WOUND HEALING AND COATING AND PROTECTION OF BIOLOGICAL ORGANS - The present invention relates to a biological film-forming agent which is for facilitating wound healing and coating and protecting biological organs, and for coating and protecting damaged cells, wound surfaces, organs and damaged sites of organs, and wound surfaces reaching soft tissues such as muscle and facia, periosteum or bone cortex. Provided is a biological film-forming agent for suppressing exudation of intracellular fluid from damaged cells, suppressing expansion of inflammation reactions and secondary inflammation reactions resulting from production of fibrin and eliminating adverse effects caused by formation of stabilised fibrin on healing. Various problems can be solved by using the agent containing aluminium chloride, cyclodextrin and water as base components. | 05-19-2016 |
| 20160375038 | HORMONE TREATMENT FOR AGE-RELATED HEARING LOSS-PRESBYCUSIS - Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the US alone. There are currently no FDA-approved drugs on the market in the US, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness. Age-related hearing loss (ARHL) is one of the most common forms of permanent hearing loss and deafness. ARHL is the #1 neurodegenerative disorder, #1 communication disorder, and 1 of the top 3 chronic medical conditions (along with arthritis & cardiovascular diseases) of our aged population. The incidence of ARHL is increasing due to the “Baby Boomers” reaching old age, and cumulative effects of lifetime noise exposure, and widespread use of chemotherapeutic and antibiotic drugs, which are ototoxic, or have ototoxic side effects. A new drug is disclosed to prevent or slow the progression of ARHL, based upon natural, existing FDA-approved compounds that are on the market to treat other non-ARHL biomedical problems. When given in the proper dosage the compounds have few, if any side effects, and initial evidence supports the effectiveness of the drug from in vitro experiments, and in vivo studies of aging mice, indicating is usefulness in preventing/treating one of the most pervasive forms of permanent hearing loss. | 12-29-2016 |
